IDO1高表达与肺鳞癌临床分期及不良预后相关

Correlation between IDO1 Expression and the Clinical Stage and Poor Prognosis in Lung Squamous Cell Carcinoma

目的探讨不同分期肺鳞癌组织中IDO1的表达情况及与预后的关系.方法纳入河北医科大学附属医院邢台市人民医院胸外科自2017年1月至2019年1月开展手术根治的肺鳞癌患者,留取患者术中癌组织标本,用免疫组织化学染色法检测IDO1的表达情况,并对患者进行术后随访.结果肺鳞癌组织中有IDO1蛋白表达,且临床Ⅱ~Ⅲ期阳性细胞数显著高于Ⅰ期.截止随访结束时,30例患者中28例存活,2例死亡,疾病稳定22例(73.3%),疾病进展8例(26.7%).IDO1高表达组和低表达组的无进展生存期(PFS)分别为26个月和40个月,差异具有统计学意义(P<0.05);高临床分期和低临床分期PFS分别为33个月和40个月,差异具有统计学意义(P<0.05).结论IDO1在肺鳞癌中表达量与临床分期有关,临床分期越高表达量越高,患者预后也越差;IDO1能指导临床分期和预后.

Objective To investigate the expression of IDO1 in different stages of lung squamous cell carcinoma and its relationship with prognosis.MethodsPatients with lung squamous cell carcinoma who underwent radical surgery in the Department of thoracic surgery of Xingtai People's Hospital Affiliated to Hebei Medical University from January 2017 to January 2019 were included.Intraoperative cancer tissue samples were taken.The expression level of IDO1 was detected by immunohistochemical staining,and the patients were followed up after operation.Results IDO1 protein was expressed in lung squamous cell carcinoma,and the number of positive cells in clinical stagesⅡ~Ⅲwas significantly higher than that in stage I.By the end of the follow-up,28 of the 30 patients had survived,2 died,22 had stable disease(73.3%),and 8 had disease progression(26.7%).The progression free survival(PFS)ofidolhigh expression group andidollow expression group were 26 months and 40 months respectively(P<0.05).The PFS of higher clinical stage and lower clinical stage were 33 months and 40 months respectively(P<0.05).Conclusion The expression level of IDO1 in lung squamous cell carcinoma was related to the clinical stage.The higher the clinical stage,the higher the expression level,and the worse the prognosis of patients.IDO1 expression level can be used to guide the clinical staging and prognosis in lung squamous cell carcinoma.